checkAd

     145  0 Kommentare MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence - Seite 2

    MedBright AI Investments Inc.
    Trevor Vieweg, Chief Executive Officer
    604-602-0001
    Email: investors@medbright.ai

    Cautionary Statement Regarding "Forward-Looking" Information

    This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the intended use of Limmi’s Disease Insights Platform to aid in predicting future medical information such as kidney stone recurrence and cancer risk, and the Company’s plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur.

    Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that Limmi’s Disease Insights Platform will be able to predict future medical information such as kidney stone recurrence and cancer risk, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the use of Limmi’s Disease Insights Platform will not be able to predict future medical information such as kidney stone recurrence and cancer risk, and the risk that the Company’s portfolio of investments will not generate returns for shareholders.

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence - Seite 2 VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) - MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is pleased to announce that the Limmi Disease Insights Platform is now being used in hospitals with …